Dee E. Silver

Neurology

9850 Genesee Ave Ste 740
La Jolla, CA 92037

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Journal: Neurology. Clinical practice

Published: March 01, 2017

Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.

Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.

Journal: Neurology

Published: April 06, 2016

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.

Journal: CNS drugs

Published: April 21, 2015

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: October 14, 2013

Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

Journal: The neurologist

Published: November 03, 2011

Showing 1-5 of 5

Last Updated: 09/26/2026